SCHEMBL3763255

SCHEMBL3763255

Cc1ccc(-c2ccc(N3CCN(CC(=O)N4CCN(C5CCC5)CC4)CC3)nn2)cc1C

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.43
NPC1 O15118 7/20 0.41
RAB9A P51151 6/20 0.41
LMNA P02545 1/20 0.40
THRB P10828 1/20 0.40
KMT2A Q03164 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
GRM5 P41594 3/20 0.40
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
SMO Q99835 1/20 0.38
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
PDK1 Q15118 1/20 0.37
PDK2 Q15119 1/20 0.37
PDK3 Q15120 1/20 0.37
PDK4 Q16654 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3780493 0.92 GRM5 (0.41) HRH3HTTNPSR1GRM5CYP11B1
SCHEMBL3776104 0.92 GRM5 (0.49) HRH3GRM5CYP11B1CYP11B2
SCHEMBL3779376 0.90 HRH3 (0.46) HRH3NPC1RAB9ATHRBNPSR1
SCHEMBL3767453 0.90 HRH3 (0.45) HRH3NPC1RAB9ALMNAKMT2A
SCHEMBL3773912 0.89 HRH3 (0.44) HRH3NPC1RAB9AHTTNPSR1
SCHEMBL3771707 0.88 GRM5 (0.46) HRH3NPC1RAB9AKMT2AHTT
SCHEMBL3771420 0.87 HRH3 (0.41) HRH3NPC1RAB9AGRM5CYP11B1
SCHEMBL3767885 0.87 HRH3 (0.43) HRH3KMT2ANPSR1CYP11B1CYP11B2
SCHEMBL3767484 0.86 MAPK1 (0.49) HRH3NPC1RAB9ATHRBKMT2A
SCHEMBL3774276 0.86 PANK3 (0.42) HRH3KMT2ANPSR1GRM5CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 HRH3 2/4885NPC1 3462/4885RAB9A 3824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.